VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Conditions: Chronic Hepatitis B Interventions: Drug: VIR-2218 and peginterferon alfa-2a Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Endocrinology | Hepatitis | Hepatitis B | Pegasys | Research | Urology & Nephrology